{
    "nctId": "NCT01793948",
    "briefTitle": "Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer",
    "officialTitle": "A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Obesity",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Changes in the phosphorylation of proteins after metformin exposure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be post-menopausal women; post-menopausal women are defined as: (1) those \\>= 50 years of age who had not menstruated during the preceding 12 months or who had castrate follicle-stimulating hormone levels (\\> 40 IU/L), (2) those who had undergone a bilateral oophorectomy\n* Patients must be at elevated risk for breast cancer based on strong family history or a history of breast biopsy documenting atypical hyperplasia anytime in the past; for this study strong family history is defined as having:\n\n  * 1 first-degree (parent, offspring, sibling) relative =\\< 50 years old when diagnosed with breast cancer, or\n  * \\>= 2 first-degree relatives of any age when diagnosed with breast cancer, or\n  * \\>= 2 second-degree (aunts, uncles, grandparents, grandchildren, nieces, nephews, or half-siblings) maternal or paternal relatives diagnosed with breast cancer and at least 1 diagnosed at =\\< 50 years of age\n* Patients must have a body mass index (BMI) \\>= 25.0 as calculated by the formula: weight in pounds / height squared x 703 = BMI; a BMI of:\n\n  * 18.5-24.9 is considered normal;\n  * 25.0-29.9 is considered overweight;\n  * 30.0+ is regarded as obese\n* Patients must be willing to complete a bilateral mammogram at baseline with repeat exam after 12 cycles of protocol therapy; patients who have had a mammogram within 1 month prior to registration to protocol therapy will not need to repeat the exam\n* Patients must be willing to provide a core tissue biopsy at baseline and with repeat tissue collection after 12 cycles of protocol therapy\n* White blood cell (WBC) \\>= 3.0 x 109/L\n* Granulocytes (polymorphs + bands) \\>= 1.5 x 109/L\n* Platelets \\>= 100 x 109/L\n* Hemoglobin \\>= 110 g/L\n* Aspartate aminotransferase (AST) =\\< 1.8 X upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =\\< 1.8 X ULN\n* Alkaline phosphatase =\\< 2 X ULN\n* Serum creatinine =\\< 115 umol/L (1.3mg/dL)\n* Serum bilirubin =\\< institution ULN (except for subjects with Gilbert's Disease who are eligible despite elevated serum bilirubin level)\n* 12 hour fasting glucose level \\< 7.0 mmol/L\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 within 28 days of registration\n* Life expectancy of \\>= 5 years\n* Subjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physician\n* Subject consent and authorization for the release of health information must be obtained according to local institutional guidelines\n\nExclusion Criteria:\n\n* No history of any malignancy except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for \\>= 5 years\n* No known diabetes (type 1 or 2) or baseline fasting glucose \\>= 7.0 mmol/L\n* No known hypersensitivity or intolerance to metformin\n* No condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as New York Heart Association \\[NYHA\\] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)\n* No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason\n* No breastfeeding\n* No concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, insulin-like growth factor 1 (IGF-1) or their receptors",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}